| MeSH term | MeSH ID | Detail |
|---|---|---|
| Leukemia | D007938 | 74 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Liver Cirrhosis | D008103 | 67 associated lipids |
| Hematoma | D006406 | 5 associated lipids |
| Demyelinating Diseases | D003711 | 15 associated lipids |
| Peripheral Nervous System Diseases | D010523 | 33 associated lipids |
| Lymphoproliferative Disorders | D008232 | 7 associated lipids |
| Crohn Disease | D003424 | 12 associated lipids |
| Osteoarthritis, Knee | D020370 | 13 associated lipids |
| Arthritis, Infectious | D001170 | 8 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Wilson CH et al. | Prospective randomised trial of the use of Daclizumab in renal transplantation using kidneys from non heart beating donors. | 2004 | Ann. Transplant. | pmid:15478912 |
| Muraki Y et al. | Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients. | 2011 Oct-Dec | Ann. Transplant. | pmid:22210422 |
| Boratyńska M et al. | Conversion from cyclosporine-based immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection. | 2006 | Ann. Transplant. | pmid:17494290 |
| Foroncewicz B et al. | A comparison between two tacrolimus-based immunosuppression regimens in renal transplant recipients: 7-year follow-up. | 2013 | Ann. Transplant. | pmid:23896824 |
| Grochowiecki T et al. | A retrospective study of steroid elimination in simultaneous pancreas and preemptive kidney transplant (Sppre-Ktx) recipients. | 2006 | Ann. Transplant. | pmid:17494291 |
| Rhu J et al. | Clinical Implication of Mycophenolic Acid Trough Concentration Monitoring in Kidney Transplant Patients on a Tacrolimus Triple Maintenance Regimen: A Single-Center Experience. | 2017 | Ann. Transplant. | pmid:29180612 |
| Mocchegiani F et al. | Tacrolimus and Everolimus de novo versus minimization of standard dosage of Tacrolimus provides a similar renal function at one year after liver transplantation: a case-control matched-pairs analysis. | 2014 | Ann. Transplant. | pmid:25347718 |
| Fox BD et al. | Tacrolimus Levels Are Not Associated with Risk of Malignancy in Lung Transplant Recipients. | 2017 | Ann. Transplant. | pmid:29133776 |
| Rehman S et al. | Effect of different tacrolimus levels on early outcomes after kidney transplantation. | 2014 | Ann. Transplant. | pmid:24509826 |
| Legris T et al. | Humoral immunity after kidney transplantation: impact of two randomized immunosuppressive protocols. | 2013 | Ann. Transplant. | pmid:24231646 |
| Hakeam HA et al. | Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients. | 2008 | Ann. Transplant. | pmid:18566560 |
| Bäckman L and Persson CA | An observational study evaluating tacrolimus dose, exposure, and medication adherence after conversion from twice- to once-daily tacrolimus in liver and kidney transplant recipients. | 2014 | Ann. Transplant. | pmid:24637379 |
| Gijsen VM et al. | Tacrolimus-induced nephrotoxicity and genetic variability: a review. | 2012 Apr-Jun | Ann. Transplant. | pmid:22743729 |
| Urbanowicz T et al. | Induction therapy, tacrolimus plasma concentration, and duration if intensive care unit stay are risk factors for peripheral leucopenia following heart transplantation. | 2014 | Ann. Transplant. | pmid:25274118 |
| Baron PW et al. | Post-Transplant Diabetes Mellitus After Kidney Transplant in Hispanics and Caucasians Treated with Tacrolimus-Based Immunosuppression. | 2017 | Ann. Transplant. | pmid:28533501 |
| Furmańczyk A et al. | Atypical calcineurin inhibitor-induced haemolytic uremic syndrome after liver transplantation. | 2009 Oct-Dec | Ann. Transplant. | pmid:20009155 |
| Gerlach UA et al. | Aspergillus spondylodiscitis after multivisceral transplantation. | 2009 Oct-Dec | Ann. Transplant. | pmid:20009156 |
| Malinowski M et al. | Effect of tacrolimus dosing on glucose metabolism in an experimental rat model. | 2010 Jul-Sep | Ann. Transplant. | pmid:20877268 |
| Roan JN et al. | Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation. | 2013 | Ann. Transplant. | pmid:23792500 |
| Tanaka T et al. | Evaluation of immune function under conversion from Prograf to Advagraf in living donor liver transplantation. | 2013 | Ann. Transplant. | pmid:23792533 |
| El-Agroudy AE et al. | Long-term graft outcome in patients with chronic allograft dysfunction after immunosuppression modifications. | 2008 | Ann. Transplant. | pmid:19034223 |
| Miyata Y et al. | Pharmacokinetics of a Once-Daily Dose of Tacrolimus Early After Liver Transplantation: With Special Reference to CYP3A5 and ABCB1 Single Nucleotide Polymorphisms. | 2016 | Ann. Transplant. | pmid:27503662 |
| Mizuno S et al. | Combination assays for evaluation of immune function and CYP3A5 genotype to identify the risk of infectious complications and mortality in living donor liver transplant patients. | 2013 | Ann. Transplant. | pmid:23845965 |
| Herden U et al. | Early Initiation of Everolimus After Liver Transplantation: A Single-Center Experience. | 2016 | Ann. Transplant. | pmid:26842532 |
| Grenda R et al. | Evaluation of the genetic background of standard-immunosuppressant-related toxicity in a cohort of 200 paediatric renal allograft recipients--a retrospective study. | 2009 Jul-Sep | Ann. Transplant. | pmid:19644155 |
| Figurski MJ et al. | Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters. | 2012 Jan-Mar | Ann. Transplant. | pmid:22466911 |
| Acott P and Babel N | BK virus replication following kidney transplant: does the choice of immunosuppressive regimen influence outcomes? | 2012 Jan-Mar | Ann. Transplant. | pmid:22466913 |
| Bułanowski M et al. | Influence of conversion from cyclosporine A to tacrolimus on insulin sensitivity assessed by euglicaemic hyperinsulinemic clamp technique in patients after kidney transplantation. | 2012 Jul-Sep | Ann. Transplant. | pmid:23018257 |
| Baran DA and Galin ID | "One size fits all": immunosuppression in cardiac transplantation. | 2003 | Ann. Transplant. | pmid:12848376 |
| Ogura Y et al. | Early Conversion From Twice-Daily Tacrolimus to Prolonged-Release Tacrolimus in Liver Transplantation: A Single-Center Experience. | 2016 | Ann. Transplant. | pmid:27432248 |
| Dedinská I et al. | Waist circumference as an independent risk factor for NODAT. | 2015 | Ann. Transplant. | pmid:25791039 |
| Eguchi S et al. | Intentional conversion from tacrolimus to cyclosporine for HCV-positive patients on preemptive interferon therapy after living donor liver transplantation. | 2007 | Ann. Transplant. | pmid:18344932 |
| Zahn A et al. | Mycophenolate mofetil combination therapy improves survival after liver transplantation. A single-center retrospective analysis. | 2013 | Ann. Transplant. | pmid:24088725 |
| WÅ‚odarczyk Z et al. | Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients. | 2002 | Ann. Transplant. | pmid:12465429 |
| Park S et al. | Reduced Tacrolimus Trough Level Is Reflected by Estimated Glomerular Filtration Rate (eGFR) Changes in Stable Renal Transplantation Recipients: Results of the OPTIMUM Phase 3 Randomized Controlled Study. | 2018 | Ann. Transplant. | pmid:29891834 |
| Rostaing L et al. | The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study. | 2014 | Ann. Transplant. | pmid:25017487 |
| Jannot M et al. | Early conversion from twice-daily tacrolimus to once-daily extended formulation in renal transplant patients before hospital discharge. | 2014 | Ann. Transplant. | pmid:24999809 |
| Provenzani A et al. | The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients. | 2009 Jan-Mar | Ann. Transplant. | pmid:19289993 |
| Urbanowicz T et al. | Comparison of conventional tacrolimus versus prolong release formula as initial therapy in heart transplantation. | 2014 | Ann. Transplant. | pmid:24949728 |
| Fuchs U et al. | Incidence of malignant neoplasia after heart transplantation--a comparison between cyclosporine a and tacrolimus. | 2014 | Ann. Transplant. | pmid:24953848 |
| Hošková L et al. | Comparison of Cystatin C and NGAL in Early Diagnosis of Acute Kidney Injury After Heart Transplantation. | 2016 | Ann. Transplant. | pmid:27226081 |
| Wu P et al. | Polymorphisms in CYP3A5*3 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients. | 2011 Jan-Mar | Ann. Transplant. | pmid:21436775 |
| Bösmüller C et al. | Tacrolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplantation: results of a prospective randomized trial. | 2012 | Ann. Transplant. | pmid:23274323 |
| Olczak-Kowalczyk D et al. | The status of dental and jaw bones in children and adolescents after kidney and liver transplantation. | 2012 | Ann. Transplant. | pmid:23274327 |
| Zakliczyński M et al. | Clinical application of monitoring mycophenolic acid trough concentration in heart transplant recipients--single center's experience. | 2005 | Ann. Transplant. | pmid:16218032 |
| Schnitzbauer AA et al. | Delayed bottom-up and amended simple method of dosing with once-daily tacrolimus application to achieve stable trough levels in liver transplantation. | 2015 | Ann. Transplant. | pmid:25553853 |
| Garlicki M et al. | Conversion from cyclosporine to tacrolimus improves renal function and lipid profile after cardiac transplantation. | 2006 | Ann. Transplant. | pmid:17025026 |
| Ruangkanchanasetr P et al. | Beta Cell Function and Insulin Resistance After Conversion from Tacrolimus Twice-Daily to Extended-Release Tacrolimus Once-Daily in Stable Renal Transplant Recipients. | 2016 | Ann. Transplant. | pmid:27980321 |
| Van Laecke S et al. | Effect of Magnesium Supplements on Insulin Secretion After Kidney Transplantation: A Randomized Controlled Trial. | 2017 | Ann. Transplant. | pmid:28848225 |
| Kitazawa F et al. | Pharmacokinetic Interaction Between Tacrolimus and Fentanyl in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. | 2017 | Ann. Transplant. | pmid:28947731 |
| Hirano Y et al. | Prolonged Administration of Twice-Daily Bolus Intravenous Tacrolimus in the Early Phase After Lung Transplantation. | 2017 | Ann. Transplant. | pmid:28798289 |
| Illsinger S et al. | Effect of tacrolimus on energy metabolism in human umbilical endothelial cells. | 2011 Apr-Jun | Ann. Transplant. | pmid:21716189 |
| Duvoux C et al. | Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection. | 2015 | Ann. Transplant. | pmid:25588713 |
| Mijal J et al. | Formation of synapses between dendritic cells and lymphocytes in skin lymph in an allogeneic reaction. | 2002 | Ann. Transplant. | pmid:12854345 |
| Albano L et al. | Dosing of Enteric-Coated Mycophenolate Sodium Under Routine Conditions: An Observational, Multicenter Study in Kidney Transplantation. | 2016 | Ann. Transplant. | pmid:27122116 |
| Thölking G et al. | Tacrolimus Concentration/Dose Ratio is Associated with Renal Function After Liver Transplantation. | 2016 | Ann. Transplant. | pmid:27003330 |
| Holechek MJ | Medication review: FK 506. | 1991 | ANNA J | pmid:1708982 |
| Schmid FX | Prolyl isomerase: enzymatic catalysis of slow protein-folding reactions. | 1993 | Annu Rev Biophys Biomol Struct | pmid:7688608 |
| Sigal NH and Dumont FJ | Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. | 1992 | Annu. Rev. Immunol. | pmid:1375473 |
| Tzakis AG et al. | Intestinal transplantation. | 1994 | Annu. Rev. Med. | pmid:7515221 |
| Hanauer SB and Dassopoulos T | Evolving treatment strategies for inflammatory bowel disease. | 2001 | Annu. Rev. Med. | pmid:11160781 |
| Pratt WB | The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase. | 1997 | Annu. Rev. Pharmacol. Toxicol. | pmid:9131255 |
| Nikitin AV | [Mechanisms of nephrotoxic action of immunodepressants, calcineurine inhibitors]. | 2014 | Antibiot. Khimioter. | pmid:25051716 |
| Romano S et al. | FK506 binding proteins as targets in anticancer therapy. | 2010 | Anticancer Agents Med Chem | pmid:21182472 |
| Epand RF and Epand RM | The new potent immunosuppressant FK-506 reverses multidrug resistance in Chinese hamster ovary cells. | 1991 | Anticancer Drug Des. | pmid:1714737 |
| Jachez B et al. | Reversion of the P-glycoprotein-mediated multidrug resistance of cancer cells by FK-506 derivatives. | 1993 | Anticancer Drugs | pmid:7683935 |
| Yamamoto M et al. | Cyclosporin A and FK506 reverse anthracycline resistance by altering the cell cycle. | 1995 | Anticancer Drugs | pmid:7579561 |
| Pourtier-Manzanedo A et al. | FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. | 1991 | Anticancer Drugs | pmid:1724925 |
| Mizuno K et al. | Modulation of multidrug resistance by immunosuppressive agents: cyclosporin analogues, FK506 and mizoribine. | 1992 Jan-Feb | Anticancer Res. | pmid:1373592 |
| Pinsk V et al. | Complete Reversion of Familial Adenomatous Polyposis Phenotype Associated with Tacrolimus and Mycophenolate Mofetil Treatment Following Kidney Transplantation. | 2017 | Anticancer Res. | pmid:28551651 |
| Kalas W et al. | FK506 restores sensitivity of thymic lymphomas to calcium-mediated apoptosis and the inducible expression of Fas ligand. | 2003 Mar-Apr | Anticancer Res. | pmid:12820430 |
| Harada N et al. | Serum Asunaprevir and Daclatasvir Concentrations and Outcomes in Patients with Recurrent Hepatitis C Who Have Undergone Living Donor Liver Transplantation. | 2018 | Anticancer Res. | pmid:30194210 |
| Ling G et al. | Mycophenolate Mofetil Alone and in Combination with Tacrolimus Inhibits the Proliferation of HT-29 Human Colonic Adenocarcinoma Cell Line and Might Interfere with Colonic Tumorigenesis. | 2018 | Anticancer Res. | pmid:29848681 |
| Morisaki T et al. | A combination of cyclosporin-A (CsA) and interferon-gamma (INF-gamma) induces apoptosis in human gastric carcinoma cells. | 2000 Sep- Oct | Anticancer Res. | pmid:11131636 |
| Gornet JM et al. | Severe CPT-11-induced diarrhea in presence of FK-506 following liver transplantation for hepatocellular carcinoma. | 2001 Nov-Dec | Anticancer Res. | pmid:11911319 |
| Del Poeta M et al. | Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. | 2000 | Antimicrob. Agents Chemother. | pmid:10681348 |
| Gao L et al. | Synergistic Effects of Tacrolimus and Azoles against Exophiala dermatitidis. | 2017 | Antimicrob. Agents Chemother. | pmid:28923863 |
| Morikawa K et al. | Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. | 1994 | Antimicrob. Agents Chemother. | pmid:7532933 |
| Onyewu C et al. | Targeting the calcineurin pathway enhances ergosterol biosynthesis inhibitors against Trichophyton mentagrophytes in vitro and in a human skin infection model. | 2007 | Antimicrob. Agents Chemother. | pmid:17664323 |
| Lamoth F et al. | In vitro activity of calcineurin and heat shock protein 90 Inhibitors against Aspergillus fumigatus azole- and echinocandin-resistant strains. | 2013 | Antimicrob. Agents Chemother. | pmid:23165466 |
| Onyewu C et al. | Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. | 2003 | Antimicrob. Agents Chemother. | pmid:12604527 |
| Fortwendel JR et al. | Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus. | 2009 | Antimicrob. Agents Chemother. | pmid:19015336 |
| Lamping E et al. | Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei. | 2009 | Antimicrob. Agents Chemother. | pmid:19015352 |
| Katiyar SK et al. | Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance. | 2012 | Antimicrob. Agents Chemother. | pmid:23027185 |
| Vaes M et al. | Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome. | 2012 | Antimicrob. Agents Chemother. | pmid:23027198 |
| Morikawa K et al. | Immunosuppressive activity of fosfomycin on human T-lymphocyte function in vitro. | 1993 | Antimicrob. Agents Chemother. | pmid:7509146 |
| Zhuang D et al. | Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay. | 2008 | Antimicrob. Agents Chemother. | pmid:18025114 |
| Sun S et al. | In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods. | 2008 | Antimicrob. Agents Chemother. | pmid:18056277 |
| Hashemizadeh Z et al. | Observational Study of Associations between Voriconazole Therapeutic Drug Monitoring, Toxicity, and Outcome in Liver Transplant Patients. | 2017 | Antimicrob. Agents Chemother. | pmid:28923870 |
| Coilly A et al. | Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. | 2012 | Antimicrob. Agents Chemother. | pmid:22908172 |
| Gao L and Sun Y | In vitro interactions of antifungal agents and tacrolimus against Aspergillus biofilms. | 2015 | Antimicrob. Agents Chemother. | pmid:26303797 |
| Uppuluri P et al. | Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. | 2008 | Antimicrob. Agents Chemother. | pmid:18180354 |
| Odom A et al. | The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. | 1997 | Antimicrob. Agents Chemother. | pmid:8980772 |
| Roy J et al. | The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication. | 2002 | Antimicrob. Agents Chemother. | pmid:12384349 |
| Sugita T et al. | A new calcineurin inhibitor, pimecrolimus, inhibits the growth of Malassezia spp. | 2006 | Antimicrob. Agents Chemother. | pmid:16870799 |
| Dang W et al. | Inhibition of Calcineurin or IMP Dehydrogenase Exerts Moderate to Potent Antiviral Activity against Norovirus Replication. | 2017 | Antimicrob. Agents Chemother. | pmid:28807916 |
| Dannaoui E et al. | In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. | 2009 | Antimicrob. Agents Chemother. | pmid:19451295 |
| Rivosecchi RM et al. | Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients. | 2017 | Antimicrob. Agents Chemother. | pmid:28674051 |
| Rosenwirth B et al. | Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. | 1994 | Antimicrob. Agents Chemother. | pmid:7527198 |
| Venkataramanan R et al. | Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. | 2002 | Antimicrob. Agents Chemother. | pmid:12183280 |